Medical oncology

Robyn L Ward and Nicholas J Hawkins
Med J Aust 2002; 176 (1): . || doi: 10.5694/j.1326-5377.2002.tb04258.x
Published online: 7 January 2002

Our knowledge of the biology of cancer has increased exponentially in the past 30 years. Although application of this knowledge to patient care has been modest, some important improvements in healthcare delivery are available now or expected in the near future.

  • 1 Department of Medical Oncology, St Vincent's Hospital, Darlinghurst, NSW.
  • 2 School of Medical Sciences, University of New South Wales, Sydney, NSW.


  • 1. Hong WK, Spitz MR, Lippman SM. Cancer chemoprevention in the 21st century: genetics, risk modeling, and molecular targets. J Clin Oncol 2000; 18: 9S-18S.
  • 2. Datamonitor Healthcare Reports. Cancer drugs of tomorrow: A quantitative pipeline analysis to 2005. London: Datamonitor Press, 1999: 26-70.
  • 3. Slamon DJ, Leyland-Jones B, Shak S, et al. Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. N Engl J Med 2001; 344: 783-792.
  • 4. Druker BJ, Talpaz M, Resta DJ, et al. Efficacy and safety of a specific inhibitor of the BCR-ABL tyrosine kinase in chronic myeloid leukemia. N Engl J Med 2001; 344: 1031-1037.
  • 5. Goldman JM, Druker BJ. Chronic myeloid leukemia: current treatment options. Blood 2001; 98: 2039-2042.


remove_circle_outline Delete Author
add_circle_outline Add Author

Do you have any competing interests to declare? *

I/we agree to assign copyright to the Medical Journal of Australia and agree to the Conditions of publication *
I/we agree to the Terms of use of the Medical Journal of Australia *
Email me when people comment on this article

Online responses are no longer available. Please refer to our instructions for authors page for more information.